These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32365629)

  • 1. Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization.
    Humphries MP; Bingham V; Abdullahi Sidi F; Craig SG; McQuaid S; James J; Salto-Tellez M
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics.
    Abdullahi Sidi F; Bingham V; Craig SG; McQuaid S; James J; Humphries MP; Salto-Tellez M
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry.
    Wu J; Mao L; Sun W; Yang X; Wang H; Liu X; Chi K; Huang X; Lin D
    J Clin Pathol; 2022 Jul; 75(7):452-458. PubMed ID: 33782193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities.
    Humphries MP; McQuaid S; Craig SG; Bingham V; Maxwell P; Maurya M; McLean F; Sampson J; Higgins P; Greene C; James J; Salto-Tellez M
    J Thorac Oncol; 2019 Jan; 14(1):45-53. PubMed ID: 30296485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.
    Pang C; Yin L; Zhou X; Lei C; Tong R; Huang M; Gong Y; Ding Z; Xue J; Zhu J; Wang Y; Ren L; Zhou L; Wang J; Peng F; Zhou Q; Lu Y
    J Thorac Dis; 2018 Feb; 10(2):816-824. PubMed ID: 29607153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visible- and near-infrared hyperspectral imaging for the quantitative analysis of PD-L1+ cells in human lymphomas: Comparison with fluorescent multiplex immunohistochemistry.
    Brunner A; Willenbacher E; Willenbacher W; Zelger B; Zelger P; Huck CW; Pallua JD
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Jan; 285():121940. PubMed ID: 36208576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.
    Taube JM; Roman K; Engle EL; Wang C; Ballesteros-Merino C; Jensen SM; McGuire J; Jiang M; Coltharp C; Remeniuk B; Wistuba I; Locke D; Parra ER; Fox BA; Rimm DL; Hoyt C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
    Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
    Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis.
    Shi H; Zhang W; Zhang L; Zheng Y; Dong T
    Front Immunol; 2023; 14():1265202. PubMed ID: 37822932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
    Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
    J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
    Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
    Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
    Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
    Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
    Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
    Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer.
    Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Moreno Ruiz P; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
    Capizzi E; Ricci C; Giunchi F; Zagnoni S; Ceccarelli C; Gómez BUÁ; Casolari L; Gelsomino F; Trisolini R; Fiorentino M; Ardizzoni A
    Lung Cancer; 2018 Dec; 126():9-14. PubMed ID: 30527198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine-learning-based image analysis algorithms improve interpathologist concordance when scoring PD-L1 expression in non-small-cell lung cancer.
    Haragan A; Parashar P; Bury D; Cross G; Gosney JR
    J Clin Pathol; 2024 Jan; 77(2):140-144. PubMed ID: 38071529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.